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Abstract
Background: The aim of the study was to optimize protocols for finding and identifying serum
proteins that are differentially expressed in persons with normal glucose tolerance (NGT)
compared to individuals with type 2 diabetes mellitus (T2DM).
Serum from persons with NGT and persons with T2DM was profiled using ProteinChip arrays and
time-of-flight mass spectra were generated by surface enhanced laser desorption/ionization time-
of-flight mass spectrometry (SELDI-TOF MS).
Results: Mass spectra from NGT- and T2DM-groups were compared. Fifteen proteins ranging
from 5 to 79 kDa were differentially expressed (p < 0.05). Five of these proteins showed decreased
and ten showed increased serum levels in individuals with T2DM. To be able to identify the
proteins, the complexity of the sample was reduced by fractionation approaches. Subsequently, the
purified fractions containing biomarkers were separated by one-dimensional SDS-polyacrylamide
gel electrophoresis (SDS-PAGE) in two identical lanes. Protein bands of the first lane were excised
and subjected to passive elution to recapture the biomarkers on ProteinChip arrays. The
corresponding bands of the second lane were subjected to peptide-mass fingerprinting (PMF).
Using this approach four of the differentially expressed proteins were identified as apolipoprotein
C3 (9.4 kDa), transthyretin (13.9 kDa), albumin (66 kDa) and transferrin (79 kDa). Whereas
apolipoprotein C3 and transthyretin were up-regulated, albumin and transferrin were down-
regulated in T2DM.
Conclusion:  Protocols for protein profiling by SELDI-TOF MS and protein identification by
fractionation, SDS-PAGE and PMF were optimized for serum from humans with T2DM. With these
protocols differentially expressed proteins were discovered and identified when serum from NGT-
and T2DM-individuals was analyzed.
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Background
Elevated fasting glucose levels and extended postprandial
hyperglycemia are cardinal traits of individuals with type
2 diabetes mellitus (T2DM) [1-3]. Impaired early insulin
secretory response of the pancreatic β-cell and decreased
insulin sensitivity of muscle, fat and liver cells contribute
to the state of hyperglycemia [3-5]. Prolonged hyperglyc-
emia is associated with both micro- and macrovascular
complications, which are leading causes of morbidity and
death in diabetes [6-9]. With increasing numbers of per-
sons demonstrating T2DM much attention has been paid
to finding causes for the development of deranged glucose
homeostasis. Hypotheses implicating circulating proteins
in the pathogenesis of T2DM have been tested by measur-
ing levels of these proteins in serum obtained from per-
sons with different degrees of glucose intolerance. In this
way the role of specific proteins in the development of
T2DM has been investigated with TNF-α, interleukin 6
and adiponectin as recent examples [10,11]. However,
T2DM is a complex disease with altered expression of
many genes and their products [12,13], which can be
anticipated to interact. It is therefore critical to monitor
changes in many proteins simultaneously. Our first aim
with this study was to optimize a protocol for measuring
levels of several proteins simultaneously, which were gen-
erated from serum samples obtained from persons with
normal glucose tolerance (NGT) or T2DM by surface
enhanced laser desorption/ionization time-of-flight mass
spectrometry (SELDI-TOF MS) [14]. With this proteomic
approach differentially expressed proteins or biomarkers
in individuals with NGT compared to T2DM were discov-
ered. The second aim was to develop a protocol for iden-
tification of these biomarkers. Crude serum contains
thousands of proteins [15], which made it necessary to
reduce the sample complexity. This was achieved by frac-
tionating the serum with anionic columns followed by
either size fractionation or reverse phase beads. Finally,
the proteins were separated by one-dimensional SDS-
polyacrylamide gel electrophoresis (SDS-PAGE). The
identities of the differentially expressed serum proteins
were obtained by peptide mass fingerprinting (PMF).
Results
Study subjects and their categorization
The study contained six participants, two women and four
men (Table 1). Fasting plasma glucose (FPG) concentra-
tions were obtained from the study subjects after an over-
night fast. After intake of glucose the plasma glucose con-
centration was measured at 120 min (G120). Using the
WHO classification [16] the subjects were categorized as
having NGT or T2DM. Two of the T2DM persons were
diet-treated and one was drug-treated (Subject 6).
Finding and identifying biomarkers
Protein measurements were performed on denaturated,
diluted serum samples on metal capture (IMAC30) and
cationic exchanger (CM10) surfaces. Protein profiles from
each subject were obtained with SELDI-TOF MS.
With the IMAC30 array in total 14, 15 and 25 peaks were
found in the low, intermediate and high mass range,
respectively. Out of these peaks, 12 with masses 5915,
6095, 7778, 8944, 9133, 9303, 9505, 17294, 28166,
37887, 51259 and 66355 Da were differentially expressed
between NGT- and T2DM-persons (p < 0.05). The
amounts of these proteins were calculated for each subject
by measuring the height of each peak (peak intensity).
Out of these 12 biomarkers, eight were up-regulated and
four down-regulated in T2DM (Table 2).
With the CM10 array in total 7, 10 and 21 peaks were
found in the low, intermediate and high mass range,
respectively. Out of these peaks, six with masses 8949,
9305, 9443, 13923, 66267 and 79040 Da were differen-
tially expressed between NGT- and T2DM-persons (p <
0.05). The amounts of these proteins were calculated for
each subject by measuring the height of each peak (peak
intensity). Out of the six biomarkers, four were up-regu-
lated and two down-regulated in T2DM (Figure 1, Table
2).
Three of the differentially expressed proteins (8944/8949,
9303/9305 and 66355/66267 Da) were captured on both
types of arrays. Using both the arrays, in total 15 differen-
tially expressed proteins were found. Five of these proteins
showed decreased levels and ten showed increased serum
levels in individuals with T2DM (Table 2).
The strategy of the identification work will be exemplified
by the elucidation of the identity of the 9.4 kDa biomar-
ker. When differentially expressed serum proteins are to
be identified, the complexity of the serum has to be
reduced. Such reduction was achieved by fractionating
denaturated serum using anionic spin columns. The dif-
ferent fractions were applied on normal phase (NP20)
and CM10 arrays, and analyzed by SELDI-TOF MS. The
latter surface was used for the identification work since
focus was on the differentially expressed proteins discov-
ered by CM10.
The flow through fraction of the anionic spin column had
retained biomarkers with masses 8949, 9305 and 79040
Da. Further purification was achieved by size fractiona-
tion. The two smaller proteins easily passed through the
size column, while the larger protein remained in the
retentate. The retentate was subsequently re-suspended in
60 % acetonitrile (ACN).Proteome Science 2006, 4:22 http://www.proteomesci.com/content/4/1/22
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The anionic fraction 5 (pH 3) contained the biomarkers
with masses 9305, 9443, 13923 and 66267 Da (Figure 2).
This fraction was further purified using reverse phase
beads. The 9443 and 13923 Da proteins were quite pure
in both the 20 % ACN and the 30 % ACN fractions. The
amount of the 66267 Da protein was quite low in the 20
% ACN fraction but higher in the 30 % ACN fraction (Fig-
ure 2).
The two reverse phase fractions containing the biomarkers
were speed-vacuumed, resuspended in sample buffer and
run in duplicates, parallel lanes on the gels. After staining,
gel bands in the relevant mass range were cut out and pro-
teins passively eluted. One lane of each reverse phase frac-
tion is shown in Figure 3. The eluates were applied on
NP20 arrays to confirm that the eluted proteins were iden-
tical to the initially discovered biomarkers (Figure 4).
When the mass spectral peak of the eluted protein coin-
cided with the biomarker peak of the serum mass spec-
trum, the corresponding band from the parallel lane was
excised and subjected to PMF and identified using
MALDI-TOF MS. Using this approach the 9443 Da protein
was identified as apolipoprotein C3 (apo C3), the 13923
Da protein as transthyretin (TTR), the 66267 Da protein
as albumin and the 79040 Da protein as transferrin.
Discussion
Profiling of blood proteins by SELDI-TOF MS has been
performed on blood obtained from individuals with dif-
ferent diseases e.g. breast or prostate cancer [17,18]. The
motivation of these studies has, at least in part, been the
lack of reliable diagnostic and prognostic biomarkers of
the disease states. Through large patient cohort studies,
patterns of differentially expressed serum proteins have
been discovered that with high accuracy distinguish
afflicted from healthy individuals [17]. Since such pat-
Table 1: Subject characterization and categorization
Subject Gender Age BMI Fasting glucose G120 WHO Category
years kg/m2 (mM) (mM)
1 Female 57 20.6 4.5 5.9 NGT
2 Male 65 26.3 5.5 4.9 NGT
3 Male 57 21.9 5.9 3.4 NGT
4 Male 54 30.7 7.3 7.8 T2DM
5 Male 56 26.6 8.8 10.9 T2DM
6 Female 54 23.1 14.1 21.9 T2DM
Subjects were ranked based on fasting plasma glucose concentration. The plasma glucose concentrations at 0 min (fasting) and 120 min (G120) after 
an oral glucose tolerance test were used to categorize the subjects to have normal glucose tolerance (NGT) or type 2 diabetes mellitus (T2DM). 
Gender, age and body mass index (BMI) are also listed.
Table 2: Differentially expressed proteins in serum from normal glucose tolerant and type 2 diabetes mellitus individuals
Peak (Da) Array T2DM vs. NGT
5915 IMAC30 ↑
6095 IMAC30 ↑
7778 IMAC30 ↑
8944/8949 IMAC30/CM10 ↑
9133 IMAC30 ↑
9303/9305 IMAC30/CM10 ↑
9443 CM10 ↑
9505 IMAC30 ↑
13923 CM10 ↑
17294 IMAC30 ↓
28166 IMAC30 ↓
37887 IMAC30 ↑
51259 IMAC30 ↓
66355/66267 IMAC30/CM10 ↓
79040 CM10 ↓
Amounts of serum proteins were determined by calculating heights of peaks found in SELDI-TOF mass spectra using the immobilized metal affinity 
capture (IMAC30) and cationic exchanger (CM10) arrays. Serum samples were obtained from three normal glucose tolerant (NGT) and three type 
2 diabetes mellitus (T2DM) subjects. Protein masses, after applying inclusion criteria (signal to noise ratio > 10, percentage of peaks > 20%) on the 
spectra, are indicated. Significant (p < 0.05, Mann-Whitney U-test) up- (↑) and down (↓) regulations are noted.Proteome Science 2006, 4:22 http://www.proteomesci.com/content/4/1/22
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terns are useful in themselves for diagnosis without know-
ing the identities of the differentially expressed proteins of
the pattern, often only mass/charge of these proteins have
been published [19]. In T2DM the situation is different
since the blood glucose level is a reliable and easy to meas-
ure marker of the diabetes disease state. In diabetes
research the SELDI-technology will probably therefore
not be used so much for diagnostic and prognostic pur-
poses. In contrast, the proteomic platform is highly rele-
vant as a tool for the investigation of the pathophysiology
of the disease since T2DM is polygenic [20] and levels of
many blood-borne proteins can be expected to be altered.
With this background we wanted to evaluate the useful-
ness of SELDI-TOF MS in investigating changes in expres-
sion patterns of blood proteins of individuals with T2DM.
The aim was to see whether differentially expressed pro-
teins could not only be discovered but also identified. In
the context of type 2 diabetes the SELDI-platform has
been used in a few animal studies, where it has either been
used to obtain protein patterns without identifying the
differentially expressed proteins [21-23] or to measure
quantities of already identified proteins [24-26].
The critical part of the SELDI-platform is the ProteinChip
array. The array is the surface, which adsorbs proteins of
the sample applied to the surface. The surface chemistry of
the array decides what subset of proteins will be adsorbed.
We found the cationic exchanger and immobilized metal
affinity capture surfaces to be equally efficient to retain
proteins. These experiences are in line with those of other
studies, where serum or plasma protein profiling has been
conducted [17,18,21-23,25,26]. Important aspects, when
defining the efficiency of a given chromatographic surface
to generate mass spectra showing numerous proteins, are
which energy-absorbing molecule and parameter settings
of the mass spectrometer are used. In the present study we
used sinapinic acid (SPA) as energy absorbing molecule.
Furthermore, we used different laser energies for low,
intermediate and high molecular weight proteins. The
generated spectra were analyzed in two consecutive cycles.
Mass spectra showing the differentially expressed proteins Figure 1
Mass spectra showing the differentially expressed proteins. SELDI-TOF mass spectra showing the six differentially 
expressed serum proteins captured by cationic exchanger array. The green spectra are from individuals with normal glucose 
tolerance and the red spectra are from individuals with type 2 diabetes mellitus.Proteome Science 2006, 4:22 http://www.proteomesci.com/content/4/1/22
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With the settings used in this study the number of pro-
teins recognized in the CM10 and IMAC30 arrays was 38
and 44, respectively. More than 90 % of the peaks were
detected in the first cycle. The stringency of the settings
affects directly the number of peaks detected, which can
be increased by lowering the signal to noise ratio (S/N).
Among the discovered proteins, six proteins detected by
the CM10 array and 12 proteins detected by the IMAC30
array were differentially expressed. The fact that peaks
were recognized with such accuracy and determined as
differentially expressed relied on the reproducibility and
quantitativeness of the method, respectively. These
aspects were separately addressed and verified. Whereas
three differentially expressed proteins were captured by
both arrays, the remaining proteins were either detected
by the CM10 or IMAC30 array. These results illustrate the
usefulness of employing different arrays and binding con-
ditions, which will adsorb different subsets of proteins,
and that some proteins are common to the different sub-
sets especially when arrays have similar surface chemis-
tries.
An important aspect of the present work was to evaluate
how readily the differentially expressed proteins were
identified. The strategy was to fractionate the sample to
reduce its complexity. Proteins of the fractions were sepa-
rated by SDS-PAGE, trypsin digested and identified by
PMF. Similar strategies for proteomic profiling and iden-
tification have been used for skeletal muscle proteins [27].
When fractionating the crude serum sample, the existence
of the protein of interest, the biomarker, was verified by
applying the fraction on NP20 array and the array on
SDS-PAGE of serum fractions Figure 3
SDS-PAGE of serum fractions. Proteins of serum frac-
tions containing biomarkers were separated with one-dimen-
sional gel electrophoresis. The two reverse phase beads 
(RPB) fractions containing 20 and 30 % acetonitrile are 
shown after staining with colloidal coomassie. Bands in the 
relevant mass range were excised and eluted. The arrows 
indicate the bands containing the 9443 biomarker.
Mass spectra of serum fractions showing the 9443 Da  biomarker Figure 2
Mass spectra of serum fractions showing the 9443 Da 
biomarker. SELDI-TOF mass spectra of serum after frac-
tionation. Upper trace shows spectrum of the anionic frac-
tion 5. Middle trace shows spectrum of the reverse phase 
beads fraction with 20 % acetonitrile. Lower trace shows the 
reverse phase beads fraction with 30 % acetonitrile. The 
abundant 66 kDa protein (albumin) was reduced in reverse 
phase fraction with 20 % acetonitrile (hatched area). The 
arrow indicates the 9443 Da biomarker.Proteome Science 2006, 4:22 http://www.proteomesci.com/content/4/1/22
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which it was discovered. Fractions containing the biomar-
ker, reasonably well separated from other proteins, were
subjected to SDS-PAGE. By passively eluting bands
thought to contain biomarkers and re-applying the elu-
ates on NP20 arrays, the presence of the biomarker in a
given band could be verified by SELDI-TOF MS. When the
presence of the biomarker in the gel piece was confirmed,
a similarly obtained gel piece was subjected to trypsin
digestion and the identity of the protein obtained by PMF.
We chose to identify the six differentially expressed pro-
teins obtained with the CM10 array. This choice was
based on the fact that they would address at least two
aspects of protein identification work. The first aspect was
that many of the proteins were obscured by the 66 kDa
protein, which by its abundance was assumed and later
verified to be albumin, and needed to be separated from
it. The second aspect was that the 8.9, 9.3 and 9.4 kDa
biomarkers were aggregated. In addition, other proteins of
similar mass/charge were also present in the same mass
spectral area and different fractionation principles would
be required. We were able to obtain identities of four of
the six proteins. Although the possible biological signifi-
cance of these changes of the proteins in T2DM will be
discussed briefly below, it should be pointed out that dif-
ferential expression was based on the comparison of three
control individuals with three individuals with T2DM.
With these very low numbers, the study is more intended
as a case report and evaluation of the SELDI-platform for
diabetes work using blood samples than having implica-
tions for the understanding of the pathophysiology of the
disease.
Lowering of transferrin and albumin are characteristic
changes in inflammation [28], which may also be part of
the pathogenesis of T2DM [29]. Decreased circulating lev-
els of these proteins in T2DM have also been connected
with impaired kidney function [30]. However, the three
T2DM individuals in this study did neither have macro-
nor microalbuminurea. Increased urinary excretion of
both transferrin and albumin has, nevertheless, been
observed in normoalbuminuric patients with T2DM [31],
which may contribute to explain our findings. Lowered
levels of transferrin have previously been shown in T2DM
[32].
Increased levels of apo C3 have been observed in T2DM
and considered a cardiovascular risk factor [33,34]. Also,
increased levels of apo C3 have been shown in serum
from individuals with type 1 diabetes mellitus (T1DM)
[35].
Finally, TTR was up-regulated. The protein exists both in a
tetrameric and the 13.9 kDa monomeric form [36].
Whereas the tetrameric form promotes β-cell function, no
such effect was observed with the monomeric form [37].
In individuals with T1DM, a rise of the blood levels of the
monomeric form was observed and suggested to be asso-
ciated with the development of β-cell failure in T1DM
[37]. Consistent with this idea, mutations in the transcrip-
tion factor hepatocyte nuclear factor-1α (HNF-1α) were
associated with down-regulation of the transcription of
TTR in mutant HNF-1α cells [38] and in MODY3 patients
[39]. In another study the levels of TTR in patients with
non-insulin dependent diabetes were not affected [40]
and in inflammatory states TTR has been shown to
decrease [29].
Conclusion
In conclusion, protocols have been optimized both for
measuring protein patterns with SELDI-TOF MS and iden-
tifying biomarker proteins with PMF in sera from persons
with T2DM. Increasing the number of study subjects may
confirm the identified, differentially expressed proteins of
this study as implicated in the pathophysiology of T2DM.
Materials and methods
Chemicals
Chemicals of analytical grade and deionized water were
used. PEFAbloc®, ACN and trifluoroacetic acid (TFA) came
from Merck (Darmstadt, Germany). CHAPS was pur-
chased from Sigma (St. Louis, MO) and urea from Amer-
sham Biosciences (Uppsala, Sweden). The material used
for one-dimensional SDS-PAGE, including the NuPAGE®
Novex gels, sample buffer, running buffer, coomassie
stain and SeeBlue Plus2 pre-stained standard, all came
from Invitrogen (Carlsbad, CA). The ProteinChip arrays,
all-in-1 peptide and all-in-1 protein molecular weight
standards, Q ceramic HyperD F spin columns, reverse
phase beads and SPA came from Ciphergen (Freemont,
CA).
Mass spectrum verifying the 9443 Da biomarker Figure 4
Mass spectrum verifying the 9443 Da biomarker. Elu-
ates were re-applied on the arrays to confirm that the eluted 
protein was the discovered biomarker at 9443 Da.Proteome Science 2006, 4:22 http://www.proteomesci.com/content/4/1/22
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Study subjects
The study was performed on six subjects, two women and
four men. Whereas three subjects had NGT, three had
T2DM. The latter subjects were treated with anti-diabetes
drugs or diet. The drug treatment was discontinued two
days prior to the study. The study subjects were between
54 and 65 years old, had normal blood pressure, did not
have any other metabolic or cancerous disease, were non-
smoking and without any medication affecting insulin
secretion. All subjects had normal thyroid, liver, cardio-
pulmonary and kidney function as determined by medi-
cal history, physical examination and blood chemistry
screening. The study participants with T2DM were found
among patients at the Diabetic unit at the Medical Center,
Enköping hospital, Sweden. The control subjects were
recruited by advertisement. Written informed consent was
obtained from all participants. After a 75-g oral glucose
tolerance test (OGTT) the study participants were catego-
rized using the WHO criteria [16] as having NGT or
T2DM. The study protocol was approved by the Human
Ethics Committee at the Medical Faculty, Uppsala Univer-
sity, Uppsala, Sweden.
Oral glucose tolerance test
All subjects fasted over-night (10–12 hours). At 8:30 am
an intravenous catheter was placed in the antecubital vein.
Blood was drawn from the catheter and plasma was pre-
pared for glucose concentration measurements by collect-
ing blood in EDTA-containing tubes. After centrifugation
(2400 g) of the tubes, plasma was separated and the glu-
cose concentration was measured. Serum was prepared for
protein profiling measurements. In such blood samples
PEFAbloc® was added before the samples were allowed to
clot. The serum samples were aliquoted and stored in -
70°C until analysis. Samples for blood chemistry were
taken and analyzed according to standard procedures.
After this the subject received 75 g of glucose per os (time
point 0 min) and blood samples were collected after 120
min for glucose concentration measurements. The plasma
glucose concentrations were determined by the glucose
oxidase reaction using Granutest 250 glucose (Merck,
Darmstadt, Germany).
Measurements of protein patterns
Serum protein patterns were determined by SELDI-TOF
MS using ProteinChip arrays. Serum samples were thawn
on ice, quickly vortexed and centrifuged. Samples (50 μl)
were denaturated by adding 75 μl 50 mM Trizma® base
buffer (pH 9) containing 9 M urea and 2 % CHAPS. The
samples were vortexed for 30 min at 4°C and centrifuged
(12,000 g) for 5 min. Finally, the samples were diluted by
mixing 5 μl denaturated serum with 245 μl binding buffer
defined below.
Two types of arrays with different surface chemistries were
used to capture proteins from the serum samples. IMAC30
arrays were activated by washing the spots during 5 min
with 50 μl 100 mM copper(II)sulphate twice. The cop-
per(II)sulphate solution was discarded, the arrays were
placed in a Bioprocessor (Ciphergen) and briefly washed
with water. Then the arrays were equilibrated during 2 × 5
min with binding buffer consisting of 100 mM sodium
phosphate (pH 6) after which the denaturated, diluted
serum samples (100 μl) were applied on the spots of the
arrays. The Bioprocessor was sealed and left at room tem-
perature (RT) on a shaker for 1 hour. The excess sample
was then discarded and the arrays were washed three
times with 125 μl sodium phosphate buffer (pH 6) during
5 min. The arrays were finally quickly washed twice with
water, removed from the Bioprocessor and allowed to air
dry. Saturated solution of SPA was prepared by mixing 5
mg SPA with 100 μl 100 % ACN and 100 μl 1 % TFA. The
saturated SPA solution was diluted to 50 % and 2 × 1 μl
was applied to every spot. The spots were air dried in
between.
CM10 arrays were equilibrated during 2 × 5 min with
binding buffer consisting of 100 mM acetate buffer (pH
4). The arrays were placed in the Bioprocessor, after which
the denaturated, diluted serum samples (100 μl) were
applied on the spots of the arrays. Binding and washing
steps were performed as described for IMAC30, using ace-
tate buffer instead of phosphate buffer.
The arrays were placed in the SELDI MS, and time-of-flight
spectra were generated by averaging several laser shots at
different laser intensities, depending on which mass
region was studied. For the low molecular weight range (2
to 50 kDa) the following settings were used: laser intensity
220, detector sensitivity 8 and optimization range 2–10
kDa. The mass accuracy was calibrated externally using
the All-in-1-peptide molecular weight standard. For the
intermediate molecular weight range (5 to 70 kDa) the
following settings were used: laser intensity 220, detector
sensitivity 8 and optimization range 5–15 kDa. The mass
accuracy was calibrated externally using the All-in-1-pro-
tein molecular weight standard. For the high molecular
weight range (15 to 150 kDa) the following settings were
used: laser intensity 240, detector sensitivity 8 and optimi-
zation range 15–50 kDa. The mass accuracy was calibrated
externally using the All-in-1-protein molecular weight
standard. Peak normalization, peak detection and align-
ment were performed with Ciphergen ProteinChip Soft-
ware 3.1.
Biomarker discovery requires the method to be reproduc-
ible and quantitative. Reproducibility of the arrays was
addressed by applying four equal aliquots of a serum sam-
ple onto spots of the arrays. The intensities of three peaksProteome Science 2006, 4:22 http://www.proteomesci.com/content/4/1/22
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were determined for each spot. The coefficient of variance
was less than 10 % for all three peaks. Quantitation of the
arrays was tested by diluting a serum sample and intensi-
ties of three peaks were determined for each dilution. The
peak intensities decreased as the sample was diluted and
showed strong linear correlations (r2>0.95) when plotted
against the logarithm of the dilutions.
Analysis
Mass spectra of serum protein patterns were obtained
from each subject. The ProteinChip software settings for
peak detection were set at a quite rigorous level. The first
pass S/N was set at 10, and the peak had to be present in
20 % of the spectra. For a given peak to be considered for
comparison, the mass error had to be < 0.3 %. Peaks were
selected for further analysis if their heights were signifi-
cantly different when comparison was performed
between the NGT- and T2DM-groups using the Mann-
Whitney U-test.
Serum protein identification
Identities of biomarkers, which are differentially dis-
played proteins obtained by SELDI-TOF MS, were
obtained by PMF. The procedure involved sample frac-
tionation, SDS-PAGE of fractionated serum samples, elu-
tion and verification of biomarkers, excision of relevant
gel bands, in gel trypsin digestion, mass determination of
the tryptic fragments and peptide database comparison.
The first step in identifying the biomarkers was to reduce
sample complexity by anionic fractionation using Q
ceramic HyperD F spin columns. The columns were first
equilibrated with a 50 mM Trizma® base buffer with 0.9 M
urea and 0.2 % CHAPS. Denaturated serum (250 μl) was
diluted with another 250 μl of the same buffer and bound
to the resin during 30 min on a mixer at RT. The column
was then centrifuged (1 min, 500 g) and the flow through
fraction was collected into an eppendorf tube. The col-
umn was then step-wise washed with 500 μl of buffers
with pH 9, 7, 5, 4, 3 or organic buffer. The fractions were
applied on both NP20 arrays and the arrays, which were
used when discovering the biomarkers.
To further purify the anionic fractions, size fractionation
with microcon YM-50 columns (Millipore, Billerica, MA)
or hydrophobic fractionation using reverse phase beads
were used. When performing the size fractionation, the
sample was added to the size fractionation column and
concentrated by centrifugation. With repeated washing
steps using increasing percentage of ACN (10 %, 20 %, 30
%, 40 %, 50 % and 60 %) in 0.1 % TFA solution, the
serum sample was further purified. These fractions were
also analyzed with NP20 arrays, to locate the biomarker
proteins to the different fractions.
When performing the hydrophobic fractionation, serum
proteins were bound to reverse phase beads during 30
min shaking at RT. Beads were spun down by centrifuga-
tion and the supernatant was removed. Subsequently, the
beads were shaken with increasing percentage of ACN (10
%, 20 %, 30 %, 40 %, 50 % and 60 %) and fractions
removed between washing steps. The hydrophobic frac-
tions were also analyzed on NP20 arrays.
Fractions containing the proteins of interest were speed-
vacuumed in a concentrator (Eppendorf, Hamburg, Ger-
many) to remove the buffer. Subsequently, the pellets
were resuspended with NuPAGE® sample buffer. The frac-
tions were resolved by applying samples in parallel lanes
on NuPAGE® Novex 4–12 % Bis-Tris gels. Also, a SeeBlue
Plus2 pre-stained standard was run on the gel. After elec-
trophoresis, the gels were stained with colloidal coomas-
sie stainer and scanned. From the first lane protein bands
of the relevant masses were excised, cut into smaller pieces
and passively eluted. The elution was achieved by placing
the gel pieces into a micro tube and shaken for 30 min in
300 μl of solution containing 50 % water, 40 % methanol
and 10 % ACN. Afterwards the solution was removed and
the bands were washed with 200 μl of 50 % ACN in 50
mM ammonium bicarbonate buffer (pH 8). After 30 min
shaking, the buffer was removed and the gel pieces dehy-
drated for 15 min in 200 μl 100 % ACN. Subsequently,
the ACN was removed and the gel pieces were heated dur-
ing 5 min in a thermo block (60°C). Approximately 30 μl
of an elution buffer consisting of 45% formic acid, 30 %
ACN, 10 % isopropanol and 15 % water was added to the
tubes, which were vortexed briefly and left on a shaker at
RT over-night. Subsequently, 1 μl of the eluent was
applied on an NP20 array, to see if the biomarker protein
had been eluted from the gel.
When eluates contained biomarkers, the corresponding
band of the second lane was excised and de-stained. In-gel
digestion was performed with trypsin essentially as
described [41]. Proteins were identified by PMF with the
search program Mascot (Matrix Science, London, UK).
SWISS-PROT was used as the protein sequence database
and the peptide masses were compared to the theoretical
peptide masses of all available proteins from mammalian
taxonomy. The criteria used to accept identifications
included the extent of sequence coverage, number of pep-
tides matched and molecular weight search (MOWSE)
score. Information about identified protein and putative
function was found at the SWISS-PROT database at the
ExPASy Molecular Biology Server [42].
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